Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

171 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
HGF/MET and the Immune System: Relevance for Cancer Immunotherapy.
Papaccio F, Della Corte CM, Viscardi G, Di Liello R, Esposito G, Sparano F, Ciardiello F, Morgillo F. Papaccio F, et al. Among authors: morgillo f. Int J Mol Sci. 2018 Nov 14;19(11):3595. doi: 10.3390/ijms19113595. Int J Mol Sci. 2018. PMID: 30441809 Free PMC article. Review.
Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor.
Tuccillo C, Romano M, Troiani T, Martinelli E, Morgillo F, De Vita F, Bianco R, Fontanini G, Bianco RA, Tortora G, Ciardiello F. Tuccillo C, et al. Among authors: morgillo f. Clin Cancer Res. 2005 Feb 1;11(3):1268-76. Clin Cancer Res. 2005. PMID: 15709198
Combination of standard chemotherapy and targeted agents.
Bareschino MA, Morgillo F, Ciardiello F. Bareschino MA, et al. Among authors: morgillo f. J Thorac Oncol. 2007 May;2(5 Suppl):S19-23. doi: 10.1097/01.JTO.0000268636.02709.b4. J Thorac Oncol. 2007. PMID: 17457224 Free article. Review. No abstract available.
Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells.
Cascone T, Morelli MP, Morgillo F, Kim WY, Rodolico G, Pepe S, Tortora G, Berrino L, Lee HY, Heymach JV, Ciardiello F. Cascone T, et al. Among authors: morgillo f. J Cell Physiol. 2008 Sep;216(3):698-707. doi: 10.1002/jcp.21444. J Cell Physiol. 2008. PMID: 18381602
171 results